Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2013

01-11-2013 | Original Article

Hepatogenous Diabetes in Cirrhosis Is Related to Portal Pressure and Variceal Hemorrhage

Authors: Hyo Keun Jeon, Moon Young Kim, Soon Koo Baik, Hong Jun Park, Hoon Choi, So Yeon Park, Bo Ra Kim, Jin Heon Hong, Ki Won Jo, Seung Yong Shin, Jung Min Kim, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Young Ju Kim, Seung Hwan Cha, Dong Joon Kim, Ki Tae Suk, Gab Jin Cheon, Young Don Kim, Dae Hee Choi, Sung Joon Lee

Published in: Digestive Diseases and Sciences | Issue 11/2013

Login to get access

Abstract

Background and Aim

The clinical impact and complications of hepatogenous diabetes (HD) on cirrhosis have not been elucidated. This study aimed to evaluate the relationship of HD with portal hypertension (PHT) and variceal hemorrhage and to assess the prevalence of HD.

Methods

From July 2007 to December 2009, 75-g oral glucose tolerance test and insulin resistance (IR) were evaluated for 195 consecutive cirrhotic liver patients (M:F = 164:1, 53.0 ± 10.2 years) who had no history of diabetes mellitus. IR was calculated using the homeostasis model of assessment-insulin resistance (HOMA-IR) formula. Endoscopy for varices, hepatic venous pressure gradient (HVPG), and serologic tests were also conducted.

Results

HD was observed in 55.4 % (108/194) of the patients. Among them, 62.0 % required OGTT for diagnosis because they did not show an abnormal fasting plasma glucose level. The presence of HD showed a significant correlation with high Child–Pugh’s score, variceal hemorrhage, and HVPG (p = 0.004, 0.002, and 0.019, respectively). In multivariate analysis, Child–Pugh’s score (OR 1.43, 95 % CI 1.005–2.038) and HVPG (OR 1.15, 95 % CI 1.003–2.547) had significant relationships with HD. Patients with recent variceal hemorrhages (within 6 months) exhibited significantly higher glucose levels at 120 min in OGTT compared to patients without hemorrhages (p = 0.042). However, there was no difference in fasting glucose levels. The 120-min glucose level and HOMA-IR score were significantly and linearly correlated with HVPG (r 2 = 0.189, p < 0.001 and r 2 = 0.033, p = 0.011, respectively).

Conclusion

HD and IR have significant relationships with PHT and variceal hemorrhage. Postprandial hyperglycemia in particular had a significant relationship with variceal hemorrhage.
Literature
1.
go back to reference Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract. 1990;8:29–36.PubMedCrossRef Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract. 1990;8:29–36.PubMedCrossRef
2.
go back to reference Buzzelli G, Chiarantini E, Cotrozzi G, et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver. 1988;8:354–359.PubMedCrossRef Buzzelli G, Chiarantini E, Cotrozzi G, et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver. 1988;8:354–359.PubMedCrossRef
3.
go back to reference Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2:1051–1056.PubMedCrossRef Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2:1051–1056.PubMedCrossRef
4.
go back to reference Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677–681.PubMedCrossRef Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677–681.PubMedCrossRef
5.
go back to reference Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol. 2006;101:70–75.PubMedCrossRef Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol. 2006;101:70–75.PubMedCrossRef
6.
go back to reference Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20:119–125.PubMed Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20:119–125.PubMed
7.
go back to reference Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22:24–27.PubMedCrossRef Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22:24–27.PubMedCrossRef
8.
go back to reference Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–938.PubMedCrossRef Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–938.PubMedCrossRef
9.
go back to reference Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280–282.PubMedCrossRef Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280–282.PubMedCrossRef
10.
go back to reference Lebrec D. Methods to evaluate portal hypertension. Gastroenterol Clin N Am. 1992;21:41–59. Lebrec D. Methods to evaluate portal hypertension. Gastroenterol Clin N Am. 1992;21:41–59.
11.
go back to reference Kim MY, Baik SK, Yea CJ, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2009;21:1241–1246.PubMedCrossRef Kim MY, Baik SK, Yea CJ, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2009;21:1241–1246.PubMedCrossRef
12.
go back to reference Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep. 2003;3:279–288.PubMedCrossRef Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep. 2003;3:279–288.PubMedCrossRef
13.
go back to reference Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007;46:927–934.PubMedCrossRef Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007;46:927–934.PubMedCrossRef
14.
go back to reference Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–1751.PubMedCrossRef Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–1751.PubMedCrossRef
15.
go back to reference Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–744.PubMedCrossRef Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–744.PubMedCrossRef
16.
go back to reference Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis. 2006;10:459–479, vii–viii. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis. 2006;10:459–479, vii–viii.
17.
go back to reference Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Clin Mol Hepatol. 2012;18:1–21.CrossRef Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Clin Mol Hepatol. 2012;18:1–21.CrossRef
18.
go back to reference Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335–348.PubMedCrossRef Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335–348.PubMedCrossRef
19.
go back to reference Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2010;16:347–352.PubMedCrossRef Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2010;16:347–352.PubMedCrossRef
20.
go back to reference Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800–809.PubMed Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800–809.PubMed
21.
go back to reference Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42:S85–S92.PubMedCrossRef Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42:S85–S92.PubMedCrossRef
22.
go back to reference Pardy BJ, Spencer RC, Dudley HA. Hepatic reticuloendothelial protection against bacteremia in experimental hemorrhagic shock. Surgery. 1977;81:193–197.PubMed Pardy BJ, Spencer RC, Dudley HA. Hepatic reticuloendothelial protection against bacteremia in experimental hemorrhagic shock. Surgery. 1977;81:193–197.PubMed
23.
go back to reference Pugliese D, Lee SS, Koshy A, et al. Systemic and splanchnic hemodynamic effects of intravenous hypertonic glucose in patients with cirrhosis. Hepatology. 1988;8:643–646.PubMedCrossRef Pugliese D, Lee SS, Koshy A, et al. Systemic and splanchnic hemodynamic effects of intravenous hypertonic glucose in patients with cirrhosis. Hepatology. 1988;8:643–646.PubMedCrossRef
24.
go back to reference Moreau R, Chagneau C, Heller J, et al. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose. Scand J Gastroenterol. 2001;36:303–308.PubMedCrossRef Moreau R, Chagneau C, Heller J, et al. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose. Scand J Gastroenterol. 2001;36:303–308.PubMedCrossRef
25.
go back to reference Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF. Bacterial translocation in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock. Gastroenterology. 1993;104:1722–1726.PubMed Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF. Bacterial translocation in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock. Gastroenterology. 1993;104:1722–1726.PubMed
26.
go back to reference Kruszynska YT, Harry DS, Bergman RN, McIntyre N. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia. 1993;36:121–128.PubMedCrossRef Kruszynska YT, Harry DS, Bergman RN, McIntyre N. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia. 1993;36:121–128.PubMedCrossRef
27.
go back to reference Cavallo-Perin P, Cassader M, Bozzo C, et al. Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect. J Clin Invest. 1985;75:1659–1665.PubMedCrossRef Cavallo-Perin P, Cassader M, Bozzo C, et al. Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect. J Clin Invest. 1985;75:1659–1665.PubMedCrossRef
28.
go back to reference Petrides AS. Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis. Zeitschrift fur Gastroenterologie. 1999;15–21. Petrides AS. Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis. Zeitschrift fur Gastroenterologie. 1999;15–21.
29.
go back to reference Muller MJ, Willmann O, Rieger A, et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology. 1992;102:2033–2041.PubMed Muller MJ, Willmann O, Rieger A, et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology. 1992;102:2033–2041.PubMed
30.
go back to reference Camma C, Petta S, Di Marco V, et al. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology. 2009;49:195–203.PubMedCrossRef Camma C, Petta S, Di Marco V, et al. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology. 2009;49:195–203.PubMedCrossRef
31.
go back to reference Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3:33–40.PubMedCrossRef Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3:33–40.PubMedCrossRef
Metadata
Title
Hepatogenous Diabetes in Cirrhosis Is Related to Portal Pressure and Variceal Hemorrhage
Authors
Hyo Keun Jeon
Moon Young Kim
Soon Koo Baik
Hong Jun Park
Hoon Choi
So Yeon Park
Bo Ra Kim
Jin Heon Hong
Ki Won Jo
Seung Yong Shin
Jung Min Kim
Jae Woo Kim
Hyun Soo Kim
Sang Ok Kwon
Young Ju Kim
Seung Hwan Cha
Dong Joon Kim
Ki Tae Suk
Gab Jin Cheon
Young Don Kim
Dae Hee Choi
Sung Joon Lee
Publication date
01-11-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2802-y

Other articles of this Issue 11/2013

Digestive Diseases and Sciences 11/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine